-
公开(公告)号：US11504417B2
公开(公告)日：2022-11-22
申请号：US16632090
申请日：2018-07-17
申请人： VIRTECH BIO, INC.
摘要： Methods for making hemoglobin based blood substitute preparations and hemoglobin based blood substitute preparations. The methods involve preparing a low purity erythrocyte protein fraction comprising hemoglobin protein and endogenous non-hemoglobin protein complement, and chemically modifying the proteins in the protein fraction to form a cross-linked hemoglobin containing blood substitute preparation. The low purity erythrocyte protein preparation can contain from at least about 0.2% (mole/mole) up to about 20% (mole/mole) endogenous non-hemoglobin protein complement. At least about 90% (mole/mole) of the hemoglobin proteins can be cross-linked, so that the average molecular mass of cross-linked proteins comprising hemoglobin protein molecules in the preparation is at least about 300 kDa. The preparations can be used to prepare finished blood substitute formulations for in-vivo and ex-vivo use.
-
公开(公告)号：US20230241184A1
公开(公告)日：2023-08-03
申请号：US18002806
申请日：2021-06-23
申请人： VirTech Bio, Inc
摘要： Pharmaceutical formulations to prevent or treat hemorrhagic shock are provided. The pharmaceutical formulations comprise an oxygenation complement comprising a hemoglobin-based oxygen carried (HBOC) and blood plasma. Related methods to prepare the pharmaceutical preparations are also provided. Furthermore, methods to prevent or treat hemorrhagic shock are provided.
-
公开(公告)号：US20200222510A1
公开(公告)日：2020-07-16
申请号：US16632090
申请日：2018-07-17
申请人： VIRTECH BIO, INC.
摘要： Methods for making hemoglobin based blood substitute preparations and hemoglobin based blood substitute preparations. The methods involve preparing a low purity erythrocyte protein fraction comprising hemoglobin protein and endogenous non-hemoglobin protein complement, and chemically modifying the proteins in the protein fraction to form a cross-linked hemoglobin containing blood substitute preparation. The low purity erythrocyte protein preparation can contain from at least about 0.2% (mole/mole) up to about 20% (mole/mole) endogenous non-hemoglobin protein complement. At least about 90% (mole/mole) of the hemoglobin proteins can be cross-linked, so that the average molecular mass of cross-linked proteins comprising hemoglobin protein molecules in the preparation is at least about 300 kDa. The preparations can be used to prepare finished blood substitute formulations for in-vivo and ex-vivo use.
-
公开(公告)号：US20230090172A1
公开(公告)日：2023-03-23
申请号：US18053482
申请日：2022-11-08
申请人： VIRTECH BIO, INC.
摘要： Methods for making hemoglobin based blood substitute preparations and hemoglobin based blood substitute preparations. The methods involve preparing a low purity erythrocyte protein fraction comprising hemoglobin protein and endogenous non-hemoglobin protein complement, and chemically modifying the proteins in the protein fraction to form a cross-linked hemoglobin containing blood substitute preparation. The low purity erythrocyte protein preparation can contain from at least about 0.2% (mole/mole) up to about 20% (mole/mole) endogenous non-hemoglobin protein complement. At least about 90% (mole/mole) of the hemoglobin proteins can be cross-linked, so that the average molecular mass of cross-linked proteins comprising hemoglobin protein molecules in the preparation is at least about 300 kDa. The preparations can be used to prepare finished blood substitute formulations for in-vivo and ex-vivo use.
-
公开(公告)号：US20210352887A1
公开(公告)日：2021-11-18
申请号：US17284668
申请日：2019-10-11
申请人： VirTech Bio, Inc.
IPC分类号： A01N1/02
摘要： Oxygenation constituents and finished oxygenation media, as well as methods of making oxygenation constituents and finished oxygenation media are provided. The oxygenation constituents comprise a hemoglobin preparation, and a red blood cell preparation. The oxygenation constituents comprise from about 10% to about 99% by weight hemoglobin of the hemoglobin preparation and the balance by weight hemoglobin of the oxygenation constituents comprise a red blood cell preparation. The finished oxygenation media comprise the oxygenation constituents and one or more other ingredients such as a diluent, or excipient. The finished oxygenation media can be used to ex-vivo preserve organs or tissue.
-
-
-
-
搜索结果
5 条记录 (耗时 0.013 秒)
